Introduction：Basic information about CAS 871266-63-6|PCI-27483, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | PCI-27483 |
|---|
| CAS Number | 871266-63-6 | Molecular Weight | 596.569 |
|---|
| Density | 1.7±0.1 g/cm3 | Boiling Point | / |
|---|
| Molecular Formula | C26H24N6O9S | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | L-Aspartic acid, N-[2-[5-[6-(aminoiminomethyl)-1H-benzimidazol-2-yl]-5'-(aminosulfonyl)-2',6-dihydroxy[1,1'-biphenyl]-3-yl]acetyl] |
|---|
| Synonym | More Synonyms |
|---|
PCI-27483 BiologicalActivity
| Description | PCI-27483 is a FVIIa/tissue factor inhibitor, with antitumour effects. |
|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Cancer |
|---|
| In Vitro | PCI-27483 inhibits the TF:FVIIa-complex induced phosphorylation of ERK1/2 and subsequent induction of c-fos in BxPC3 cells, a human pancreatic adenocarcinoma line that highly expresses TF. Furthermore, PCI-27483 blocks the TF:FVIIa induced secretion of IL8 in both BxPC3 cells and MDA-MB-231 breast cancer cells[2]. |
|---|
| In Vivo | PCI-27483 shows dose-dependent inhibition of thrombus formation, fibrin accumulation and PT. PCI-27483 (4 mg/kg) shows comparable anticoagulation effects as 2 mg/kg enoxaparin[1]. PCI-27483 (0 and 90 mg/kg, s.c.) results in inhibition of tumor growth in CD1 nu/nu mice implanted with BxPC3 cells[2]. |
|---|
| References | [1]. Gómez-Outes A, et al. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis. 2011 Feb;5(1):33-59. [2]. Julia Prescott, et al. PCI-27483, a small molecule inhibitor of Factor VIIa, inhibits growth of BxPC3 pancreatic adenocarcinoma xenograft tumors. Cancer Research May 2008 Volume 68, Issue 9 Supplement. |
|---|
Chemical & Physical Properties
| Density | 1.7±0.1 g/cm3 |
|---|
| Molecular Formula | C26H24N6O9S |
|---|
| Molecular Weight | 596.569 |
|---|
| Exact Mass | 596.132568 |
|---|
| PSA | 291.25000 |
|---|
| LogP | -0.74 |
|---|
| Index of Refraction | 1.775 |
|---|
| InChIKey | WDJHHCAKBRKCLW-IBGZPJMESA-N |
|---|
| SMILES | N=C(N)c1ccc2nc(-c3cc(CC(=O)NC(CC(=O)O)C(=O)O)cc(-c4cc(S(N)(=O)=O)ccc4O)c3O)[nH]c2c1 |
|---|
Synonyms
| L-Aspartic acid, N-[2-[5-[6-(aminoiminomethyl)-1H-benzimidazol-2-yl]-5'-(aminosulfonyl)-2',6-dihydroxy[1,1'-biphenyl]-3-yl]acetyl]- |
| L-Aspartic acid, N-[[5-[5-(aminoiminomethyl)-1H-benzimidazol-2-yl]-5'-(aminosulfonyl)-2',6-dihydroxy[1,1'-biphenyl]-3-yl]acetyl]- |
| (S)-2-[[2-[5-(5-Carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]acetyl]amino]succinic acid |
| PCI27483/PCI-27483 |
| N-{[5-(5-Carbamimidoyl-1H-benzimidazol-2-yl)-2',6-dihydroxy-5'-sulfamoyl-3-biphenylyl]acetyl}-L-aspartic acid |
| PCI-27483 |
